1 September 2020 - Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost effectiveness watchdog NICE decided that there was no need to review it.

After EU approval in April Novo said it had priced Rybelsus at parity with rival GLP-1 drugs in the UK, and NICE will not perform a single technology appraisal as a result, allowing the company to begin negotiations in England and Wales to get the drug included on NHS formularies.

The Scottish Medicine Consortium will make a decision on whether to reimburse the drug later this year, while NICE will consider including it in national prescription guidelines.

Read Pharmaphorum article